- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07616206
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems (Hybrid CATT1)
Hybrid CATT1: Hybrid Closed Loop Insulin Pumps With Cadisegliatin as Adjunctive Treatment in Patients With Type 1 Diabetes A Phase 2a Double Blind Randomized Cross-Over Study
TTP399-206 is a Phase 2a multicenter double blind cross over randomized study of cadisegliatin in participants with T1D using hybrid closed loop systems to manage their diabetes. Participants using a hybrid closed loop insulin pump to manage their diabetes will be randomized to either receive blinded cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment or placebo QD along with their insulin treatment. The trial begins with a screening period of up to 2 weeks, followed by a device training and insulin adjustment period of 1-2 weeks leading into the first double-blind treatment period of 6 weeks. There will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participants will cross-over to the treatment that they did not receive in the first treatment period.
연구 개요
상세 설명
TTP399-206 is a 20 week, Phase 2a trial designed to evaluate efficacy and safety of cadisegliatin in participants with T1D who are using hybrid closed loop (HCL) systems to manage their condition to gather preliminary data to understand how cadisegliatin performs in an HCL setting.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Meaghan Marnell
- 전화번호: (336) 888-0435
- 이메일: clinicaltrials@vtvtherapeutics.com
연구 장소
-
-
California
-
Modesto, California, 미국, 95355
- 모병
- Paradigm Clinical Research -Modesto
-
수석 연구원:
- Gopika Gangupantula, MD
-
San Diego, California, 미국, 92108
- 모병
- Paradigm Clinical Research Centers, LLC
-
수석 연구원:
- Schafer Boeder, MD
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- Barbara Davis Center for Diabetes
-
수석 연구원:
- Halis Kaan Akturk, MD
-
-
Georgia
-
Atlanta, Georgia, 미국, 30318
- 모병
- Atlanta Diabetes Associates
-
수석 연구원:
- Bruce W Bode, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27514
- 모병
- UNC Eastowne Medical Office Building
-
수석 연구원:
- Klara Klein, MD, PhD
-
-
Texas
-
Austin, Texas, 미국, 78731
- 모병
- Texas Diabetes & Endocrinology, P.A.
-
수석 연구원:
- Thomas Blevins, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- Participants >= 18 years of age
- Fasting C-peptide levels <0.6 ng/ml
- Average TIR < 70% recorded on their personal CGM data collected over the past 7 days prior to Visit 1
- Currently on a hybrid closed loop device for at least 3 months and willing to stay on the same model of pump device for study duration
- Willing to wear a study provided CGM for study duration
- Total bilirubin ≤2×ULN, ALT and AST ≤3×ULN
Key Exclusion Criteria:
- Have Type 2 Diabetes Mellitus (DM), monogenic diabetes, maturity-onset diabetes, other unusual or rare forms of DM, or diabetes resulting from a secondary disease.
- Have been hospitalized for DKA within 3 months
- Have uncontrolled hypothyroidism or hyperthyroidism
- Have QTcF interval > 450 msec for males or > 470 msec for females
- Have a personal or family history of long QT syndrome, Torsades de pointes, or other complex ventricular arrhythmias
- Have persistent, uncontrolled hypertension
- Have clinically significant cardiovascular or cerebrovascular disease
- Have proliferative retinopathy or maculopathy requiring acute treatment
- Have a serious concomitant systemic disorder including but not limited to HIV or active Hep B or Hep C
- Have been diagnosed and/or treated for malignancy within 3 years
- Have used any of the following medications within the specified time periods: any non-insulin anti-diabetic therapies (e.g.SGLT-2 inhibitors, GLP-1 receptor agonists, metformin, sulfonylureas, DPP-4 inhibitors, pramlintide, a-glucosidase inhibitors, or glucose dependent insulinotropic polypeptide agonists) within 30 days, antipsychotic medications (e.g. olanzapine, risperidone, clozapine, quetiapine, and haloperidol) within 30 days, systemic corticosteroids for ≥7 days for a temporary medical condition within 30 days,
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Cadisegliatin 800 mg QD, then Placebo
If a participant is randomized to receive cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment in the first double-blind treatment period of 6 weeks, there will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participant will cross-over to the placebo QD along with their insulin treatment |
Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin
다른 이름들:
Placebo (insulin alone) |
|
실험적: Placebo, then Cadisegliatin 800 mg QD
If a participant is randomized to receive placebo QD along with their insulin treatment in the first double-blind treatment period of 6 weeks, there will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participant will cross-over to the cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment |
Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin
다른 이름들:
Placebo (insulin alone) |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
To assess the change in Time in Range (TIR)
기간: last 2 weeks of the two 6-week treatment periods
|
Time in Range (TIR) based on study CGM in participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo |
last 2 weeks of the two 6-week treatment periods
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
CGM-based metric for glycemic control
기간: last 2 weeks of each treatment period
|
Time In Tight Range (TITR) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
기간: last 2 weeks of each treatment period
|
Time Above Range (TAR) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
기간: last 2 weeks of each treatment period
|
Time Below Range (TBR) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
기간: last 2 weeks of each treatment period
|
Glucose Management Indicator (GMI) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
기간: last 2 weeks of each treatment period
|
Glucose variability (GV) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
기간: last 2 weeks of each treatment period
|
Time in Range (TIR) > 70% |
last 2 weeks of each treatment period
|
|
Change in glucose control after standardized mixed meal tolerance test (MMTT)
기간: 12 weeks
|
Glucose Peak Plasma Concentration (Cmax) based on study CGM after standardized mixed meal tolerance test (MMTT) |
12 weeks
|
|
Change in glucose control after standardized mixed meal tolerance test (MMTT)
기간: 12 weeks
|
Glucose Area under the plasma concentration versus time curve (AUC) based on study CGM after standardized mixed meal tolerance test (MMTT) |
12 weeks
|
|
To assess the change in Level 1, Level 2 , and Level 3 hypoglycemic incidence
기간: 12 weeks
|
Number of events of Level 1 and Level 2 hypoglycemia as determined by CGM and Level 3 hypoglycemic events in participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo |
12 weeks
|
|
Assess incidence of Serious Adverse Events (SAEs)
기간: 14 weeks
|
Number of Serious Adverse Events (SAEs) |
14 weeks
|
|
Assess incidence of Treatment Emergent Adverse Events (TEAEs)
기간: 14 weeks
|
Number of treatment emergent adverse events (TEAEs) |
14 weeks
|
|
Assess incidence of Treatment Emergent Adverse Events (TEAEs) leading to discontinuation
기간: 14 weeks
|
Number of treatment emergent adverse events (TEAEs) leading to discontinuation of study drug |
14 weeks
|
|
Assess incidence of Adverse Events of Special Interest (AESIs)
기간: 14 weeks
|
Number of adverse events of special interest (AESIs) |
14 weeks
|
|
Change from baseline in average daily total insulin dose
기간: last week of the two 6-week treatment periods
|
Change from baseline in average daily total insulin dose in units (IU) based on manual entry in eDiary records from participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo |
last week of the two 6-week treatment periods
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Maria Alba, MD, vTv Therapeutics LLC
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
- TTP399-206
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .